US EditionBlood Test Can Predict Melanoma Recurrence
- NYU Langone Health scientists led a study, published April 15, 2025, assessing melanoma recurrence prediction using ctDNA.
- Standard methods struggle to detect recurrence, so researchers sought better ways to spot cancer activity early.
- Researchers analyzed blood samples from nearly 600 stage III melanoma patients in the COMBI-AD clinical trial.
- David Polsky stated that ctDNA tests offer a clear measure of the disease itself, unlike tissue analyses.
- Detecting ctDNA post-surgery identifies high-risk patients, suggesting ctDNA tests may guide melanoma treatment decisions.
27 Articles
27 Articles
Y Health: Gene-based blood test may help predict early signs of cancer’s return - South Asian Daily
New Delhi, April 16 – Monitoring blood levels of DNA fragments shed by dying tumour cells may accurately predict cancer recurrence, according to a new study. Researchers at New York University-Langone Health, US, focussed on nearly 600 men and women from Europe, North America, and Australia, with stage III melanoma — among the most aggressive forms of skin cancer. The study showed that approximately 80 per cent of skin cancer patients with detec…
Gene-based blood test may help predict early signs of cancer’s...
Last Updated on April 16, 2025 by Team THIP New Delhi, April 16 (IANS) Monitoring blood levels of DNA fragments shed by dying tumour cells may accurately predict cancer recurrence, according to a new study. Researchers at New York University-Langone Health, US, focussed on nearly 600 men and women from Europe, North America, and Australia, […] The post Gene-based blood test may help predict early signs of cancer’s return appeared first on THIP M…
Circulating Tumor DNA Test May Help Predict Melanoma Recurrence
A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence. The team’s research, involving adult melanoma patients in a Phase III clinical trial (COMBI-AD) found that approximately 80% of stage III melanoma patients who had detectable levels of circulating tumor DNA (ctDNA) before they started trea…
Coverage Details
Bias Distribution
- 54% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
